Unified eCOA, validated wearable endpoints, and protocol-trained concierge support help pharma teams run decentralized and hybrid trials with confidence—while reducing site burden and preventing deviations early.
Today’s trials generate millions of signals — but only actionable, validated endpoints move programs forward. Delve Health brings eCOA, wearables, and multilingual concierge together into a single, regulatory-aligned ecosystem.
Centralized data across wearables, ePRO, and diaries
Automated compliance with human intervention when it matters
Regulatory-aligned digital endpoints (FDA, EMA, PMDA)
Real-time dashboards for global oversight
Built for Pharma Sponsors
Deploy globally, validate confidently, and keep evidence flowing—Delve combines eCOA, digital measures, consent, and analytics with a human layer that prevents drift and missed data.
Global Scale
Deploy multilingual eCOA + wearables across any region with consistent operations.
Regulatory Alignment
Fit-for-purpose validation and documentation designed for FDA/EMA review expectations.
Human Concierge
Real humans intervene when patients fall behind—recovering syncs and preventing deviations.
Real-Time Oversight
Live dashboards for safety signals, sync failures, and endpoint quality—without waiting for exports.
Unified eCOA + Wearables
Instead of juggling siloed vendors, Delve harmonizes subjective and objective data streams into a single real-time environment.
ePRO + symptom tracking with regulatory audit trails
Digital biomarkers contextualized by real-world signals
Retention Powered by Humans, Not Just Software
When a device misses a sync, a diary goes incomplete, or a patient feels lost — automation flags the issue, and our concierge team resolves it in minutes.
Proactive intervention for sync failures
Multilingual patient outreach and device troubleshooting
Scheduling, reminders, and adherence coaching
Huge reductions in missing data and protocol deviations
Proven in Drug Development
Global Phase III Program
95% retention at 12 months with concierge + wearable oversight.
Digital Endpoint Validation
Objective signals correlated with gold-standard clinical measures.
Hybrid Oncology Study
63% improvement in adherence through patient outreach programs.
95%
Device Compliance
87%
Retention at 12 Months
60%
Fewer Missed Syncs
30%
Faster Enrollment Support
Run Your Next Global Trial With Confidence.
Real-time oversight. Validated digital endpoints. Human-centered retention.